AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31915151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy or sleeve gastrectomy and biliopancreatic diversion with duodenal switch)
Number of subjects: 12
Study 31915159 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota composition and body composition profile (obesity, sarcopenia, metabolic syndrome)
Number of subjects: 300
Study 31915166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombectomy (IAT)
Number of subjects: 0
Study 31915166 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial thrombectomy (IAT) with intravenous thrombolysis (IVT) at the nearest primary stroke centre (PSC)
Number of subjects: 0
Study 31915166 — intervention group
Group type: COMPARATOR
Intervention: Centralised care at a comprehensive stroke centre (CSC)
Number of subjects: 0
Study 31915192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin exposure (6 mg/kg)
Number of subjects: 219
Study 31915192 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 219
Study 31915195 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib plus Obinutuzumab
Number of subjects: 45
Study 31915837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 40
Study 31915837 — intervention group
Group type: EXPERIMENTAL
Intervention: Global SBT LUS
Number of subjects: 40
Study 31915837 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral SBT LUS
Number of subjects: 40
Study 31915837 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic indices of filling pressures
Number of subjects: 40
Study 31915837 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral LUS
Number of subjects: 40
Study 31915837 — intervention group
Group type: EXPERIMENTAL
Intervention: Global and anterolateral SBT LUS
Number of subjects: 40
Study 31916132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 40
Study 31916132 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 40
Study 31916270 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 361
Study 31916448 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study 31916448 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 31916464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lung ultrasonography via thoracoscopy
Number of subjects: 89
Study 31916464 — intervention group
Group type: COMPARATOR
Intervention: Manual exploration of the organ by thoracotomy
Number of subjects: 89
Study 31916575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 25-g dose
Number of subjects: 0
Study 31916827 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) and light physical activity measured using Actigraph GT3X+ accelerometers
Number of subjects: 130
Study 31916865 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31917194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning (measured by Frontal Assessment Battery test)
Number of subjects: 40
Study 31917194 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Meter Walk Test (10MWT)
Number of subjects: 40
Study 31917194 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 40
Study 31917319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 31917319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Number of subjects: 0
Study 31917319 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31917843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge)
Number of subjects: 29
Study 31917843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 29
Study 31918324 — intervention group
Group type: EXPERIMENTAL
Intervention: NIU model
Number of subjects: 29010
Study 31918324 — intervention group
Group type: EXPERIMENTAL
Intervention: NIU model refitted to EPI data
Number of subjects: 29010
Study 31918324 — intervention group
Group type: EXPERIMENTAL
Intervention: NIU model for prediction of HER2-positivity in EPI
Number of subjects: 29010
Study 31918324 — intervention group
Group type: EXPERIMENTAL
Intervention: NIU model fitted to NIU data
Number of subjects: 29010
Study 31918324 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with improved variables (progesterone and oestrogen receptor expression, method of sample extraction)
Number of subjects: 29010
Study 31918531 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Conservation plus Problem-Solving Therapy
Number of subjects: 23
Study 31918531 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 23
Study 31918944 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study 31918944 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study 31919012 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 26
Study 31919012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no milrinone)
Number of subjects: 26
Study 31919092 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitor development in patients with SHB
Number of subjects: 154
Study 31919092 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic reactions in inhibitor patients
Number of subjects: 154
Study 31919092 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype association with inhibitors
Number of subjects: 154
Study 31919132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus albumin-bound paclitaxel (ABP)
Number of subjects: 37
Study 31919278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tick-borne encephalitis (TBE) vaccination
Number of subjects: 20
Study 31919404 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX every 2 weeks (adapted dose in stage two)
Number of subjects: 30
Study 31919404 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 30
Study 31919663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmological disorders present
Number of subjects: 51
Study 31919663 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular visual acuity (VA) testing not achieved
Number of subjects: 51
Study 31920324 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary and person-centered care
Number of subjects: 0
Study 31920324 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 31920571 — intervention group
Group type: EXPERIMENTAL
Intervention: KINVIS therapy combined with conventional therapeutic exercise (TherEX) for 10 days
Number of subjects: 11
Study 31920571 — intervention group
Group type: EXPERIMENTAL
Intervention: KINVIS therapy combined with conventional therapeutic exercise (TherEX)
Number of subjects: 11
Study 31920716 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational modeling-guided ablation
Number of subjects: 118
Study 31920716 — intervention group
Group type: COMPARATOR
Intervention: Empirical ablation
Number of subjects: 118
Study 31920733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicemine, NMDA receptor antagonist, dosage and duration not available
Number of subjects: 0
Study 31920733 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study 31921371 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 52
Study 31921371 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Aerobic Training (IAT)
Number of subjects: 52
Study 31921371 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 52
Study 31921432 — intervention group
Group type: EXPERIMENTAL
Intervention: SSPGA
Number of subjects: 50
Study 31921432 — intervention group
Group type: EXPERIMENTAL
Intervention: LFA-REAL
Number of subjects: 50
Study 31921432 — intervention group
Group type: EXPERIMENTAL
Intervention: SSPGA and LFA-REAL
Number of subjects: 50
Study 31921443 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in research team
Number of subjects: 380
Study 31921443 — intervention group
Group type: COMPARATOR
Intervention: Previous study without patient involvement
Number of subjects: 380
Study 31921443 — intervention group
Group type: EXPERIMENTAL
Intervention: Researchers' attitudes towards patient involvement
Number of subjects: 380
Study 31921715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid strategy intervention, details not available
Number of subjects: 0
Study 31922043 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training program including directed self-regulated learning and post-testing
Number of subjects: 32
Study 31922043 — intervention group
Group type: COMPARATOR
Intervention: Traditional simulation-based training program
Number of subjects: 32
Study 31922043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training programs
Number of subjects: 32
Study 31922084 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + Enhanced Program (SC + EP; 8 skill-building cores, monthly support sessions, targeted diet/physical activity strategies)
Number of subjects: 0
Study 31922084 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC; American Academy of Pediatrics overweight/obesity recommendations)
Number of subjects: 0
Study 31922277 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 803
Study 31922277 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease remission in anorexia nervosa (AN)
Number of subjects: 803
Study 31922277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 803
Study 31922277 — intervention group
Group type: EXPERIMENTAL
Intervention: Other specified feeding or eating disorders (OSFED)
Number of subjects: 803
Study 31922545 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC with vitamin K antagonists
Number of subjects: 1405
Study 31922545 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC with vitamin K antagonists, clinically significant depressive symptoms (PHQ-2 ≥ 3)
Number of subjects: 1405
Study 31923068 — intervention group
Group type: EXPERIMENTAL
Intervention: More acculturation (born in the United States with high English proficiency)
Number of subjects: 10006
Study 31923098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (n=1617)
Number of subjects: 6085
Study 31923098 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n=1617)
Number of subjects: 6085
Study 31923098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (n=2658)
Number of subjects: 6085
Study 31923098 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n=2658)
Number of subjects: 6085
Study 31923098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (n=1810)
Number of subjects: 6085
Study 31923098 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n=1810)
Number of subjects: 6085
Study 31923188 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mydriatic retinal photography
Number of subjects: 24
Study 31923255 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere length (TL) and telomerase activity (TA) measured during index presentation with NSTEACS.
Number of subjects: 298
Study 31923277 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial basis neural networks
Number of subjects: 2940
Study 31923277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network models (product-unit, sigmoid unit, radial basis function)
Number of subjects: 2940
Study 31923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibrastat
Number of subjects: 0
Study 31923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 31923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery denervation
Number of subjects: 0
Study 31923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreceptor device implantation
Number of subjects: 0
Study 31923641 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI-directed surveillance intervals
Number of subjects: 333
Study 31923641 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical real-time analysis of diminutive rectosigmoid adenomas
Number of subjects: 333
Study 31923641 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIC classification accuracy
Number of subjects: 333
Study 31923800 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS matched therapy
Number of subjects: 506
Study 31923800 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 506
Study 31923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall therapeutic proposal
Number of subjects: 506
Study 31923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic susceptibility testing
Number of subjects: 506
Study 31923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched treatment
Number of subjects: 506
Study 31924241 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin 1000 mg orally three times daily for 21 days before surgery
Number of subjects: 20
Study 31924299 — intervention group
Group type: EXPERIMENTAL
Intervention: ER group (patients enrolled in TARGET-AC)
Number of subjects: 131
Study 31924299 — intervention group
Group type: COMPARATOR
Intervention: NER group (patients not enrolled in TARGET-AC)
Number of subjects: 131
Study 31924299 — intervention group
Group type: EXPERIMENTAL
Intervention: ER group
Number of subjects: 131
Study 31924299 — intervention group
Group type: COMPARATOR
Intervention: NER group
Number of subjects: 131
Study 31924461 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat 84 mg single dose
Number of subjects: 14
Study 31924461 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy EM subjects (n=7)
Number of subjects: 14
Study 31924681 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic headaches (PTH+)
Number of subjects: 557
Study 31924681 — intervention group
Group type: COMPARATOR
Intervention: Nontraumatic headaches (PTH-)
Number of subjects: 557
Study 31924681 — intervention group
Group type: COMPARATOR
Intervention: Headaches in mTBI- group
Number of subjects: 557
Study 31926552 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 45
Study 31926552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-strain ratio
Number of subjects: 45
Study 31926561 — intervention group
Group type: EXPERIMENTAL
Intervention: FJS-12
Number of subjects: 120
Study 31926561 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC
Number of subjects: 120
Study 31926776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgluteal approach
Number of subjects: 3018
Study 31926776 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 3018
Study 31926776 — intervention group
Group type: COMPARATOR
Intervention: Anterior approach
Number of subjects: 3018
Study 31926776 — intervention group
Group type: EXPERIMENTAL
Intervention: All approaches
Number of subjects: 3018
Study 31927117 — intervention group
Group type: EXPERIMENTAL
Intervention: CABM patients
Number of subjects: 533
Study 31927166 — intervention group
Group type: EXPERIMENTAL
Intervention: NLG207 (formerly CRLX101) nanoparticle-drug conjugate (NDC) of camptothecin (CPT)
Number of subjects: 0
Study 31927479 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced care planning with three care intensities: intensive care, maximal medical care, and exclusive palliative care.
Number of subjects: 482
Study 31927562 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP/ZDV/3TC
Number of subjects: 40
Study 31927562 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r
Number of subjects: 40
Study 31927670 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to dietary recommendations (high adherence, 10th decile)
Number of subjects: 160
Study 31927670 — intervention group
Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 160
Study 31927670 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 160
Study 31927670 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 160
Study 31927670 — intervention group
Group type: COMPARATOR
Intervention: Consumption of vegetable added fat, sweetened food, milk and dairy products, and fruit and vegetable intakes
Number of subjects: 160
Study 31928035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapport-building behaviors
Number of subjects: 65
Study 31928035 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual exposure through initial trauma-eliciting
Number of subjects: 65
Study 31928294 — intervention group
Group type: EXPERIMENTAL
Intervention: Li81 (opicinumab)
Number of subjects: 0
Study 31928530 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 administration in GC cell lines
Number of subjects: 106
Study 31928530 — intervention group
Group type: COMPARATOR
Intervention: C3 blocker pre-incubation
Number of subjects: 106
Study 31928530 — intervention group
Group type: COMPARATOR
Intervention: JAK2 inhibitor pre-treatment
Number of subjects: 106
Study 31928530 — intervention group
Group type: EXPERIMENTAL
Intervention: High C3 deposition
Number of subjects: 106
Study 31928530 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 deposition correlation
Number of subjects: 106
Study 31929102 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotoras de Donación eLearning module
Number of subjects: 98
Study 31929543 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stents (PF-SES)
Number of subjects: 7243
Study 31929543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) regimens
Number of subjects: 7243
Study 31929554 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing free health care policy (PBF-FHC) including child nutrition services; duration from January 2015 to December 2016.
Number of subjects: 0
Study 31929554 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive and information tracks of the intervention; specific details on dosage and duration not available.
Number of subjects: 0
Study 31929554 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recruitment strategy; specific details on dosage and duration not available.
Number of subjects: 0
Study 31929554 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of inputs at the facility and patient level; specific details on dosage and duration not available.
Number of subjects: 0
Study 31930057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 21
Study 31930057 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (75 mg/day)
Number of subjects: 21
Study 31930095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Chinese Medicine (CM) herbal medication administered twice daily for eight weeks.
Number of subjects: 1500
Study 31930095 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 1500
Study 31930302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive urgency (HypUrg) patients during follow-up (FU)
Number of subjects: 469
Study 31930302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive urgency (HypUrg) patients
Number of subjects: 469
Study 31930374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol therapy (1.26 g per day)
Number of subjects: 23
Study 31930513 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS clinical pathway (CP)
Number of subjects: 133
Study 31930513 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical pathway (CP)
Number of subjects: 133
Study 31931024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)-based active cellular immunotherapy using high hydrostatic pressure-killed cancer cells derived from NSCLC cell lines.
Number of subjects: 32
Study 31931024 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TAA-specific T cells in blood of NSCLC patients using commercially available peptide mixes in an in vitro stimulation assay.
Number of subjects: 32
Study 31931768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative survey data collection in 2014, 2018, and 2021
Number of subjects: 3431
Study 31931768 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection at five time points
Number of subjects: 3431
Study 31931768 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops with intervention developers at Raising Voices
Number of subjects: 3431
Study 31931767 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional medical care as determined by treating physicians
Number of subjects: 5000
Study 31931776 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 50
Study 31931844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Number of subjects: 926
Study 31931844 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 926
Study 31931844 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between lung ultrasound and auscultation
Number of subjects: 926
Study 31931844 — intervention group
Group type: COMPARATOR
Intervention: Auscultation in non-ventilated patients
Number of subjects: 926
Study 31931900 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 50
Study 31931900 — intervention group
Group type: EXPERIMENTAL
Intervention: Water infusion
Number of subjects: 50
Study 31931900 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal-weight women)
Number of subjects: 50
Study 31932137 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120-NefTat/AS01 vaccine
Number of subjects: 16
Study 31932246 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed HEU infants
Number of subjects: 869
Study 31932246 — intervention group
Group type: COMPARATOR
Intervention: Breastfed HU infants
Number of subjects: 869
Study 31932246 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed HEU infants with healthier mothers (n=84)
Number of subjects: 869
Study 31932382 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid treatment, specific dosage and duration not available
Number of subjects: 0